bringing together oncologists and oncology-focused healthcare professionals across the Empire State
Meetings & Education
Financial Advocacy & Patient Assistance
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
ESHOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
On November 14, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
FDA granted this application priority review and zanubrutinib received orphan product and breakthrough therapy designations for treatment of MCL.
Read FDA announcement
Tweets by OSSatACCC